cbh v5 aav9 abe c terminus (Addgene inc)
Structured Review

Cbh V5 Aav9 Abe C Terminus, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 20 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cbh v5 aav9 abe c terminus/product/Addgene inc
Average 93 stars, based on 20 article reviews
Images
1) Product Images from "Therapeutic base editing alleviates restrictive cardiomyopathy"
Article Title: Therapeutic base editing alleviates restrictive cardiomyopathy
Journal: Cell Reports Medicine
doi: 10.1016/j.xcrm.2026.102639
Figure Legend Snippet: Intrathoracic ABE treatment corrects Tnni3 R193H mutation in cardiac tissue (A and B) Schematic illustration of the dual AAV9 vector construction strategy and ABE treatment, administered via intrathoracic injections in 6-week-old Tnni3 R193H/R193H mice. (C and D) Efficient correction of Tnni3 mutation in the heart. Assessment of gene editing efficiency in the hearts of Tnni3 R193H/R193H mice 12 weeks after the AAV treatment. A>G editing efficiencies were measured in genomic DNA and mRNA using high-throughput sequencing. Each point represents an individual mouse. ∗∗∗∗ p < 0.0001 based on Student’s unpaired t test analysis. Data are presented as mean ± SEM. (E and F) Lack of liver editing following the AAV9-ABE treatment. As in (C), gene editing efficiency in the livers of Tnni3 R193H/R193H mice after 12 weeks of dual AAV treatment. A>G editing efficiency was also assessed in the genomic DNA and mRNA extracted from liver tissue, demonstrating diminished delivery and expression of the ABE system in the hepatic tissue. Each point represents an individual mouse. ns, not statistically significant (Student’s unpaired t test analysis). Data are presented as mean ± SEM.
Techniques Used: Mutagenesis, Plasmid Preparation, Next-Generation Sequencing, Expressing

